Perflutren lipid microsphere

Phase 3Small molecule

IImaRx Therapeutics

Perflutren lipid microsphere is one of 60 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Prostate CarcinomaNot yet recruiting

AblationCompleted

Breast CancerPreclinical

Active, not recruiting

Prostate CarcinomaPhase 3

Not yet recruiting

AblationPreclinical

Completed

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Perflutren lipid microsphere

IImaRx Therapeutics

Phase 3

1 2

Lexiscan

Astellas

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 4

Rilvegostomig

AstraZeneca

Preclinical

1 5

Ablavar

LLantheus Medical Imaging

Preclinical

2 6

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 7

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 8

Lapatinib Plus Capecitabine

GSK

Preclinical

2 9

Therapeutic Progesterone

EEmory University

Preclinical

1 10

Trastuzuma

FFudan University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Not yet recruiting

Prostate Carcinoma

NCT06024772

Clinical

Trials by Indication[1]

ESS2 trials

SHAPE for ICP Assessment

Completed·TThomas Jefferson University·Phase 2·NCT06571786·19 enrolled

Microvascular Flow Assessment Repeatability Study: The MARS Study

Terminated·UUniversity of Pennsylvania·N/A·NCT01242020·6 enrolled

Kidney Cancer2 trials

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT03907657·15 enrolled

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT04021238·25 enrolled

Ultrasound2 trials

Contrast-enhanced Ultrasound of the Kidney

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT02684435·63 enrolled

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT03196076·25 enrolled

Ischemic stroke1 trial

Microbubble-Enhanced Clotbust Treatment of Acute Ischemic Stroke

Terminated·IImaRx Therapeutics·Phase 1/2·NCT00507806

Menopausal Women1 trial

A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease

Completed·LLantheus Medical Imaging·Phase 4·NCT00162370·400 enrolled

6 more indications

Ablation1 trial

Contrast ICE for Myocardial Scar in VT Ablations

Completed·WWeill Medical College of Cornell University·N/A·NCT03212326·24 enrolled

Prostate Cancer1 trial

Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

Completed·TThomas Jefferson University·Phase 2·NCT02967458·55 enrolled

Echocardiography1 trial

Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy

Completed·MMayo Clinic·Phase 4·NCT02880137·36 enrolled

Breast Cancer1 trial

Diagnostic Study of Early Breast Cancer Using Ultrasound

Terminated·SSunnybrook Health Sciences Centre·N/A·NCT01391039·12 enrolled

Prostate Carcinoma1 trial

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)

Not yet recruiting·TThomas Jefferson University·Phase 3·NCT06024772·300 enrolled

Acute Spinal Cord Injury1 trial

Utilizing Contrast-enhanced Ultrasound (CEUS) to Assess Critically Hypo Perfused Spinal Cord Tissue After Injury

Completed·UUniversity of Washington·Approved·NCT04056988·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Perflutren lipid microsphere. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perflutren lipid microsphere compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perflutren lipid microsphere. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ImaRx Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IImaRx Therapeutics

Perflutren lipid microsphere

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

ESS2 trials

Kidney Cancer2 trials

Ultrasound2 trials

Ischemic stroke1 trial

Menopausal Women1 trial

Ablation1 trial

Prostate Cancer1 trial

Echocardiography1 trial

Breast Cancer1 trial

Prostate Carcinoma1 trial

Acute Spinal Cord Injury1 trial

References

Drug Info

Quick Facts

Related News